EOLS logo

Evolus, Inc. Stock Price

NasdaqGM:EOLS Community·US$453.1m Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 28 Fair Values set on narratives written by author

EOLS Share Price Performance

US$7.30
-4.95 (-40.41%)
US$19.00
Fair Value
US$7.30
-4.95 (-40.41%)
61.6% undervalued intrinsic discount
US$19.00
Fair Value
Price US$7.30
AnalystConsensusTarget US$19.00

EOLS Community Narratives

AnalystConsensusTarget·
Fair Value US$19 61.6% undervalued intrinsic discount

International Expansion And Pipeline Developments Will Reshape Aesthetics Markets

1users have liked this narrative
0users have commented on this narrative
10users have followed this narrative

Snowflake Analysis

Very undervalued with exceptional growth potential.

2 Risks
4 Rewards

Evolus, Inc. Key Details

US$285.8m

Revenue

US$95.4m

Cost of Revenue

US$190.5m

Gross Profit

US$249.0m

Other Expenses

-US$58.6m

Earnings

Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
-0.90
66.63%
-20.49%
-506.9%
View Full Analysis

About EOLS

Founded
2012
Employees
329
CEO
David Moatazedi
WebsiteView website
www.evolus.com

Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Recent EOLS News & Updates

Recent updates

No updates